18 results
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
elements of our strategy to achieve our mission are:
Advance the development of CC8464 towards FDA approval for treating EM and iSFN. Based on its
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
elements of our strategy to achieve our mission are:
Advance the development of CC8464 towards FDA approval for treating EM and iSFN. Based on its
10-K
2023 FY
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
elements of our strategy to achieve our mission are:
Advance the development of CC8464 towards FDA approval for treating EM and iSFN. Based on its pre
8-K
EX-99.1
CHRO
Chromocell Therapeutics Corp.
9 Apr 24
Chromocell Issues Letter to Stockholders from Chief Executive Officer
8:30am
,
With my inaugural letter to stockholders, I am pleased to provide an update on our recent initial public offering (“IPO”), share our mission, outline … portion of his accrued compensation, affirming the belief in Chromocell’s mission.
These and other actions the Company have taken since the close
424B4
CHRO
Chromocell Therapeutics Corp.
20 Feb 24
Prospectus supplement with pricing info
5:30pm
potential for other indications of peripheral neuropathic pain. The key elements of our strategy to achieve our mission are:
Advance the development of our
424B4
x1swa9q 53lg
20 Feb 24
Prospectus supplement with pricing info
5:28pm
DRS/A
fxq fp6nuxblaxs18
17 Oct 22
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next